SIONSionna Therapeutics, Inc.
What is the market doing?
The market is leaning against it: in a downtrend (−85% vs 200-day) and heavily shorted (+10% of shares).
In a downtrend, below its 50- and 200-day averages. Oversold (RSI 18). Price is −85% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).
Heavily shorted, settled Sep 15, 2026, about a week of normal trading to cover. Down 7.7% since the previous count, down from 13.2% of shares outstanding three months ago.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How SION is trading
Sionna Therapeutics, Inc. is +193% over the past year while the S&P 500 is +18%: 174 points ahead of the market.
1-year return · S&P 500 +18%
- vs 200-day average
- −85%
vs 200-day average · a clear downtrend
- RSI (14)
- 18
RSI (14) · oversold, sold harder than it has been bought
- Below its 52-week high
- 90%
Below its 52-week high
Details›
- Last close2026-10-09
- $51.04
- 1 monthS&P 500 +2.7%
- +31%
- 1 yearS&P 500 +18%
- +193%
- vs 50-day average$11.96
- −59%
- 52-week high
- $51.03
- 52-week low
- $4.50
- Annualised volatility
- 115%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-08
- −$22M
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Biotechnology
The closest names by size in the same industry